Literature DB >> 25948677

Chemotherapy-Induced Nausea and Vomiting: Time for More Emphasis on Nausea?

Terry L Ng1, Brian Hutton2, Mark Clemons2.   

Abstract

Entities:  

Mesh：

Year:  2015        PMID： 25948677      PMCID： PMC4571780          DOI： 10.1634/theoncologist.2014-0438

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


× No keyword cloud information.
  53 in total

1.  Randomised comparison of ondansetron plus dexamethasone with dexamethasone alone for the control of delayed cisplatin-induced emesis.

Authors:  H Tsukada; T Hirose; A Yokoyama; Y Kurita
Journal:  Eur J Cancer       Date:  2001-12       Impact factor: 9.162

2.  Pilot study on the efficacy of an ondansetron- versus palonosetron-containing antiemetic regimen prior to highly emetogenic chemotherapy.

Authors:  Candice M Wenzell; Michael J Berger; Marlo A Blazer; Brooke S Crawford; Niesha L Griffith; Robert Wesolowski; Maryam B Lustberg; Gary S Phillips; Bhuvaneswari Ramaswamy; Ewa Mrozek; Joseph M Flynn; Charles L Shapiro; Rachel M Layman
Journal:  Support Care Cancer       Date:  2013-06-08       Impact factor: 3.603

3.  Gabapentin for the prevention of chemotherapy- induced nausea and vomiting: a pilot study.

Authors:  Felipe Melo Cruz; Daniel de Iracema Gomes Cubero; Patrícia Taranto; Tatiana Lerner; Andrea Thaumaturgo Lera; Michele da Costa Miranda; Mariana da Cunha Vieira; Angelo Bezerra de Souza Fêde; Fernanda Schindler; Mércia Maleckas Carrasco; Samuel Oliveira de Afonseca; Hélio Pinczowski; Auro del Giglio
Journal:  Support Care Cancer       Date:  2011-04-05       Impact factor: 3.603

4.  High efficacy of a single oral dose of ondansetron 8 mg versus a metoclopramide regimen in the prevention of acute emesis induced by fluorouracil, doxorubicin and cyclophosphamide (FAC) chemotherapy for breast cancer.

Authors:  S M Bosnjak; Z B Nesković-Konstantinović; S S Radulović; S Susnjar; L B Mitrovi
Journal:  J Chemother       Date:  2000-10       Impact factor: 1.714

5.  Aprepitant versus dexamethasone for preventing chemotherapy-induced delayed emesis in patients with breast cancer: a randomized double-blind study.

Authors:  Fausto Roila; Benedetta Ruggeri; Enzo Ballatori; Albano Del Favero; Maurizio Tonato
Journal:  J Clin Oncol       Date:  2013-12-09       Impact factor: 44.544

6.  Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy.

Authors:  M Aapro; A Fabi; F Nolè; M Medici; G Steger; C Bachmann; S Roncoroni; F Roila
Journal:  Ann Oncol       Date:  2010-01-15       Impact factor: 32.976

7.  Control of delayed nausea and vomiting with granisetron plus dexamethasone or dexamethasone alone in patients receiving highly emetogenic chemotherapy: a double-blind, placebo-controlled, comparative study.

Authors:  L Goedhals; J F Heron; J P Kleisbauer; O Pagani; C Sessa
Journal:  Ann Oncol       Date:  1998-06       Impact factor: 32.976

8.  Prospective validation of risk prediction indexes for acute and delayed chemotherapy-induced nausea and vomiting.

Authors:  N Bouganim; G Dranitsaris; S Hopkins; L Vandermeer; L Godbout; S Dent; P Wheatley-Price; C Milano; M Clemons
Journal:  Curr Oncol       Date:  2012-12       Impact factor: 3.677

9.  A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy.

Authors:  Winnie Yeo; F K F Mo; J J S Suen; W M Ho; S L Chan; W Lau; J Koh; W K Yeung; W H Kwan; K K C Lee; T S K Mok; A N Y Poon; K C Lam; E K Hui; B Zee
Journal:  Breast Cancer Res Treat       Date:  2008-03-10       Impact factor: 4.872

10.  Omission of day 2 of antiemetic medications is a cost saving strategy for improving chemotherapy-induced nausea and vomiting control: results of a randomized phase III trial.

Authors:  Paula P Lajolo; Beatriz de Camargo; Auro del Giglio
Journal:  Am J Clin Oncol       Date:  2009-02       Impact factor: 2.339
View more
  24 in total

1.  Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide.

Authors:  Mallika P Patel; Sarah Woodring; Dina M Randazzo; Henry S Friedman; Annick Desjardins; Patrick Healy; James E Herndon; Frances McSherry; Eric S Lipp; Elizabeth Miller; Katherine B Peters; Mary Lou Affronti
Journal:  Support Care Cancer       Date:  2019-08-22       Impact factor: 3.603

2.  Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting.

Authors:  Rudolph M Navari; Rui Qin; Kathryn J Ruddy; Heshan Liu; Steven F Powell; Madhuri Bajaj; Leah Dietrich; David Biggs; Jacqueline M Lafky; Charles L Loprinzi
Journal:  N Engl J Med       Date:  2016-07-14       Impact factor: 91.245

3.  Incidence of nausea and vomiting in breast cancer patients treated with anthracycline plus cyclophosphamide-based chemotherapy regimens in Italy: NAVY observational study.

Authors:  Michelino De Laurentiis; Chiara Bonfadini; Vito Lorusso; Giuseppina Cilenti; Francesca Di Rella; Giuseppe Altavilla; Manuela Otero; Antonio Ardizzoia; Paolo Marchetti; Giorgia Peverelli; Domenico Amoroso; Stefania Vecchio; Elena Fiorio; Simona Orecchia
Journal:  Support Care Cancer       Date:  2018-06-25       Impact factor: 3.603

Review 4.  Nausea and Vomiting in Advanced Cancer.

Authors:  Rudolph M Navari
Journal:  Curr Treat Options Oncol       Date:  2020-02-05

5.  Mirtazapine, a dopamine receptor inhibitor, as a secondary prophylactic for delayed nausea and vomiting following highly emetogenic chemotherapy: an open label, randomized, multicenter phase III trial.

Authors:  Jun Cao; Quchang Ouyang; Shusen Wang; Joseph Ragaz; Xiaojia Wang; Yuee Teng; Biyun Wang; Zhonghua Wang; Jian Zhang; Leiping Wang; Jiong Wu; Zhimin Shao; Xichun Hu
Journal:  Invest New Drugs       Date:  2020-02-08       Impact factor: 3.850

6.  Incidence of chemotherapy-induced nausea and vomiting among cancer patients receiving moderately to highly emetogenic chemotherapy in cancer centers in Sichuan, China.

Authors:  Yu Sun; Yuzhu Zheng; Xiaoyun Yang; Ke Xie; Chi Du; Lang He; Yan Gui; Jiangping Fu; Changlin Li; Huiling Zhang; Li Zhu; Jun Bie; Yi Sun; Yu Fu; Yangang Zhou; Feng Shou; Yan Wang; Jiang Zhu
Journal:  J Cancer Res Clin Oncol       Date:  2021-02-14       Impact factor: 4.553

7.  Efficacy of cisplatin plus vinorelbine adjuvant chemotherapy with split-dose administration of cisplatin after complete resection of stage II-IIIA non-small cell lung cancer.

Authors:  Norihiko Funaguchi; Hirotoshi Iihara; Daizo Kaito; Takenori Gomyo; Yuka Sasaki; Komei Yanase; Junki Endo; Fumitaka Ito; Chiemi Hirose; Yasushi Ohno; Hiroyuki Okura
Journal:  Mol Clin Oncol       Date:  2022-02-07

Review 8.  Delayed Chemotherapy-Induced Nausea and Vomiting: Pathogenesis, Incidence, and Current Management.

Authors:  Bernardo L Rapoport
Journal:  Front Pharmacol       Date:  2017-01-30       Impact factor: 5.810

Review 9.  Revisiting the physiology of nausea and vomiting-challenging the paradigm.

Authors:  Rita J Wickham
Journal:  Support Care Cancer       Date:  2019-08-06       Impact factor: 3.603

10.  Guidelines versus individualized care for the management of CINV.

Authors:  Mark Clemons
Journal:  Support Care Cancer       Date:  2018-03-19       Impact factor: 3.603
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.